Supplementing our understanding of vitamin D and multiple sclerosis

Neurology

Volumn 74, Issue 23, 2010, Pages 1846-1847

  Wingerchuk, Dean M ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

25 HYDROXYVITAMIN D; CALCIUM; VITAMIN D;

ABNORMAL LABORATORY RESULT; ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROL GROUP; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE ESCALATION; DRUG WITHDRAWAL; EDITORIAL; HUMAN; HYPERCALCEMIA; MULTIPLE SCLEROSIS; NEPHROLITHIASIS; OUTCOME ASSESSMENT; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; VITAMIN SUPPLEMENTATION;

EID: 77953356894     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3181e3d96c     Document Type: Editorial

References (11)

1. Handel AE, Giovannoni G, Ebers GC, Ramagopalan SV. Environmental factors and their timing in adult-onset multiple sclerosis. Nat Rev Neurol 2010;6:156-166.
2. De Jager PL, Chibnik LB, Cui J, et al. Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score. Lancet Neurol 2009;8:1111-1119.
3. Ascherio A, Bar-Or A. EBV and brain matter(s)? Neurology 2010;74:1092-1095.
4. Munger KL, Zhang SM, O'Reilly E, et al. Vitamin D intake and incidence of multiple sclerosis. Neurology 2004; 62:60-65.
5. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum 25-hydroxyvitamin D levels and risk of multiple sclerosis. JAMA 2006;296:2832-2838.
6. Smolders J, Damoiseaux J, Menheere P, Hupperts R. Vitamin D as an immune modulator in multiple sclerosis: a review. J Neuroimmunol 2008;194:7-17.
7. Tremlett H, van der Mei IA, Pittas F, et al. Monthly ambient sunlight, infections and relapse rates in multiple sclerosis. Neuroepidemiology 2008;31:271-279.
8. Embry AF, Snowdon LR, Vieth R. Vitamin D and seasonal fluctuations of gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis. Ann Neurol 2000;48:271-272.
9. Burton JM, Kimball S, Vieth R, et al. A phase I/II dose-escalation trial of vitamin D3 and calcium in multiple sclerosis. Neurology 2010;74:1852-1859.
10. Wingerchuk DM, Lesaux J, Rice GP, Kremenchutzky M, Ebers GC. A pilot study of oral calcitriol (1,25-dihydroxyvitamin D3) for relapsing-remitting multiple sclerosis. J Neurol Neurosurg Psychiatry 2005;76:1294-1296.
11. Institute of Medicine. Dietary Reference Intakes for Vitamin D and Calcium. http://www.iom.edu/Activities/Nutrition/DRIVitDCalcium.aspx. Accessed April 2, 2010